MTTI ^{225}Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ^{225}Ac-EBTATE against SSTR2 NET cancers online in the European Journal of Nuclear Medicine. ("Long acting ^{225}Ac-EBTATE is highly efficacious against somatostatin receptor-2-positive neuroendocrine tumors" (**https://rdcu.be/d2lCG**).

Professor Humphrey Fonge of the Université de Laval and lead author commented, "At just 40% of the administered dose reported for ^{225}Ac-DOTATATE, ^{225}Ac-EBTATE produces enhanced anti-tumor efficacy in Small Cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as shown with complete tumor remissions. At a therapeutic dose of 2x 34 kBq, ^{225}Ac-EBTATE showed general safety for 28 days after blood biochemistry analysis, CBC, and histopathological examination of major organs and tissues. We demonstrated that ^{225}Ac-EBTATE was effective against human small-cell lung cancer (SCLC) with 80% complete remission and 100% survival in preclinical models."

MTTI has licensed commercial use rights for the patented Evans blue (EB) technology from the National Institute of Biomedical Imaging and Bioengineering ("**NIBIB**"), part of the National Institutes of Health ("**NIH**"). This platform is the basis for the best-in-class, new generation, collection of targeted radiopharmaceuticals (TRP). EB binds to serum albumin, extending *in vivo* circulatory half-life and tumor residence time, enhancing up to 30-fold uptake at a tumor and enabling good efficacy with significantly lower radiopharmaceutical activity and fewer dosing cycles vs. the current standard of care. Our 3-year follow up of ^{177}Lu-EBTATE in patients* (N=30) with metastatic neuroendocrine tumors, demonstrated good safety with no nephro- or hepatoxicity and 86% disease control rate using only 40% of the administered dose of ^{177}Lu-DOTATATE.

Dr. Jean-Mathieu Beauregard, MD, Associate Professor of Department of Radiology of Université Laval, said, "I am encouraged to see the positive results of ^{225}Ac-EBTATE in treating small cell lung cancer and Pan-neuroendocrine tumor (NET) in preclinical studies. I look forward to working with MTTI and Professor Fonge to translate this into the clinic."

Dr. Chris Pak, President & CEO of MTTI commented "[225]Ac-EBTATE effectiveness was encouraging, paralleling the clinical superiority of ^{177}Lu-EBTATE. We look forward to collaborating with Professors Beauregard and Fonge to drive [225]Ac-EBTATE into clinical trials in 2025."

Molecular Targeting Technologies, Inc. (MTTI). Molecular Targeting Technologies, Inc. is a private, clinical stage biotech developing targeted radiopharmaceuticals (TRP) for rare cancers. MTTI is committed to building value by translating innovative TRP to improve human health. For more information: www.mtarget.com.

*Jiang Y, Liu Q, Wang G, et al. Safety and efficacy of peptide receptor radionuclide therapy with ^{177}Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. *Theranostics.* 2022;12(15):6437-6445.

Contacts
Chris Pak, cpak@mtarget.com